title: Treatment of naturally occurring bovine respiratory disease in juvenile calves with a single administration of a florfenicol plus flunixin meglumine formulation.
abstract: The efficacy and safety of a florfenicol plus flunixin meglumine formulation in the treatment of respiratory disease was evaluated in calves less than six weeks of age, compared with a positive control group treated with a well-established florfenicol formulation. A total of 210 calves, selected from nine sites in Belgium, France and Spain, showing severe signs of respiratory disease, were randomly assigned to treatment with either florfenicol plus flunixin meglumine (Resflor; MSD Animal Health) or florfenicol (Nuflor; MSD Animal Health), both administered subcutaneously once. Animals were clinically observed daily for 10 days following treatment initiation. The predominant respiratory pathogens were Pasteurella multocida, Mycoplasma bovis, Mannheimia haemolytica and Histophilus somni. All isolates were subject to in vitro sensitivity testing and found susceptible to florfenicol. In both groups, rectal temperature dropped and clinical index (depression and respiratory signs) significantly improved after treatment. Specifically, for the change in rectal temperature from pretreatment to six hours post-treatment, the florfenicol-flunixin formulation was found significantly superior to florfenicol. Moreover, the florfenicol-flunixin formulation alleviated the clinical signs of disease more rapidly, and was demonstrated to be non-inferior to florfenicol on days 4 and 10. The use of the product combining florfenicol and flunixin in calves is safe and efficacious in the treatment of outbreaks of bovine respiratory disease.
authors.affiliation: MSD Animal Health Innovation, Beaucouzé 49071, France.
authors.forename: J
authors.initials: J
authors.lastname: Thiry
authors.forename: J V
authors.initials: JV
authors.lastname: González-Martín
authors.forename: L
authors.initials: L
authors.lastname: Elvira
authors.forename: E
authors.initials: E
authors.lastname: Pagot
authors.forename: F
authors.initials: F
authors.lastname: Voisin
authors.forename: G
authors.initials: G
authors.lastname: Lequeux
authors.forename: A
authors.initials: A
authors.lastname: Weingarten
authors.forename: V
authors.initials: V
authors.lastname: de Haas
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001530:Belgium / Q000453:epidemiology; D001831:Body Temperature; D048090:Bovine Respiratory Disease Complex / Q000188:drug therapy* / Q000382:microbiology; D002417:Cattle; D003002:Clonixin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004196:Disease Outbreaks / Q000517:prevention & control / Q000662:veterinary*; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D008297:Male; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D012007:Rectum / Q000502:physiology; D012720:Severity of Illness Index; D013030:Spain / Q000453:epidemiology; D013839:Thiamphenicol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; C014558:flunixin meglumine; C035534:florfenicol; D013839:Thiamphenicol; D003002:Clonixin